Author + information
- John J.V. McMurray, BSC, MB ChB, MD∗ ()
- ↵∗Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow G12 8TA, Scotland, United Kingdom
I would like to thank Dr. Jonnalagadda and colleagues for their letter about our trial with vildagliptin (1).
With regard to the proportion of patients treated with loop diuretic agents, the data in Table 1 reflect 2 classes of drugs, “plain sulfonamides” (64.8% and 65.9%) and “high-ceiling diuretic agents and potassium-sparing agents” (6.3% and 4.8%), whereas in the “Other Measurements of Heart Failure Status” section, the data included only plain sulfonamides.
Regarding the question about “protocol deviations” versus “violations,” the term we should have used is “deviation,” as reported in Figure 2. No protocol violations were reported during the study.
I hope this information clarifies the situation.
Please note: The trial was funded by Novartis. Glasgow University received financial support for time spent working in this trial. Dr. McMurray has worked with Novartis on other trials using different drugs with the same financial arrangement.
- 2018 American College of Cardiology Foundation